cybercoin market Top snippets

Six residential plots in Wuhan received 5.457 billion yuan: OCT received 2.42 billion yuan from Yangchun Lake. According to the monitoring of the China Central Finger Research Institute, on December 13th, Wuhan successfully sold six residential plots, including Hanyang District, Donghu High-tech Zone, Hongshan District, huangpi district District and Qingshan District. The total land area of 6 plots is 214,964 ㎡, the total planned construction area is 726,285.4 ㎡, and the total starting price is 5.457 billion yuan. In the end, all six plots were sold at the reserve price, with a total income of 5.457 billion yuan, including Yangchun Lake in Hongshan District, OCT, and Hanyang District, Wuhan Huijing Real Estate, a private enterprise.The public security organs that cracked down on the rectification of the "money-changing party" found that the funds involved were more than 80 billion yuan. It was learned from the press conference of the Ministry of Public Security that in May this year, the Ministry of Public Security deployed a special work to crack down on the rectification of the "money-changing party" and derivative crimes. Since the special action, it has been found that the funds involved have flowed more than 80 billion yuan. (Xinhua News Agency)Ha Sanlian: Four kinds of drugs are planned to win the bid for national centralized procurement. Ha Sanlian announced that the company and its wholly-owned subsidiary Lanxi Pharmaceutical participated in the tenth batch of national centralized procurement of drugs organized by the state. The company's esmolol hydrochloride injection, pentoxifylline injection, potassium chloride injection, and tandospirone citrate tablets of Lanxi Pharmaceutical intend to win the bid for this centralized procurement. If the subsequent purchase contract is signed and implemented, it will help to expand the sales of related products and improve the market share and brand influence. The prices of the above-mentioned drugs are respectively 1.34 yuan for esmolol hydrochloride injection, 0.59 yuan for pentoxifylline injection, 0.16 yuan for potassium chloride injection and 6.56 yuan for tandospirone citrate tablets.

Hite Bio: Two drugs are planned to be selected for national centralized drug procurement. Hite Bio announced that the company participated in the tenth batch of national centralized drug procurement. According to the selected results released by the joint procurement, roxatidine acetate hydrochloride and pentoxifylline injection for injection of the company are selected for this centralized procurement. These two drugs are suitable for the treatment of upper gastrointestinal bleeding and peripheral arterial diseases respectively. The procurement cycle is from the date of implementation of the selected results to December 31, 2027, during which medical institutions will give priority to the use of selected drugs. The company obtained the Drug Registration Certificate of the above drugs in 2024, but it has not generated sales revenue this year. This election will help to enhance the brand influence of the company and have a positive impact on the company's development.Zhonglu Co., Ltd.: The total amount of taxes and late fees paid is 15,430,100 yuan. Zhonglu Co., Ltd. announced that the company, as a limited partner of Zhonglu Advantage, received its cash asset distribution according to the resolution of Zhonglu Advantage Partner Meeting. In view of the above-mentioned asset allocation matters, the company strictly abides by the relevant regulations and adopts the principle of "tax after distribution". As required, it has declared and paid enterprise income tax of 11,770,500 yuan and late payment fee of 3,659,500 yuan, totaling 15,430,100 yuan. The late payment fee paid by the company will be included in the current profit and loss in 2024, which is expected to affect the company's net profit attributable to shareholders of listed companies in 2024 by about 3,659,500 yuan.Astana Airlines resumed the route from Urumqi to Astana. On December 13th, according to Astana Airlines, Astana Airlines resumed the Urumqi-Astana flight from December 1st, with 2 flights per week. The resumed KC flight KC287 departs from Astana (NQZ) at 19: 30 every Tuesday and Saturday and arrives in Urumqi (URC) at 1: 00 the next day; KC288 departs from Urumchi (URC) at 2 o'clock every Wednesday and Sunday and arrives in Astana (NQZ) at 1: 45, all of which are local time. In addition, Astana Airlines also operates regular flights from Urumqi to Almaty, four times a week.

Liao Min held video talks with the heads of sovereign credit rating teams of international credit rating companies. Recently, Vice Minister of Finance Liao Min held video talks with Mary Duron, global head of Moody's Sovereignty and Local Government Risk Department, and Roberto Xifeng-Arevalo, global head of Standard & Poor's Sovereignty Rating Team, respectively, to introduce the latest incremental policies of the China government, and exchanged views with each other on issues such as government debt management, fiscal sustainability, fiscal policy supporting the high-quality development of the real economy, and fiscal and taxation system reform. Both Moody's and Standard & Poor's said that the introduction of the Ministry of Finance was comprehensive and frank, which was very helpful for them to deepen their understanding of the macro policies of the China government, and they looked forward to more exchanges between the two sides. (Ministry of Finance)Hengrui Pharma: SHR-2173 injection was approved for clinical trial. Hengrui Pharma announced that its subsidiary, Guangdong Hengrui Pharma Co., Ltd., received the Notice of Approval for Clinical Trial of SHR-2173 injection approved and issued by National Medical Products Administration, and agreed to carry out clinical trial. The indication is lupus nephritis. SHR-2173 injection is a therapeutic biological product independently developed by the company, and the research and development expenses have been invested about 45.03 million yuan. The period from research and development to listing of drugs is long, there are many links, and there are uncertain factors. The company will actively promote research and development projects and fulfill its information disclosure obligations.Guoxin Technology: Serialized chip products have been launched in the field of automotive electronic MCU. Guoxin Technology said in an investigation that the company has launched serialized chip products in the field of automotive electronic MCU in recent years, which has been welcomed by the market; Through the implementation of the strategy of "standing on the ground" and "overwhelming", this year, the company's automobile electronic MCU chip business has formed certain advantages, and obvious progress has been made in loading application and shipment volume. The product price is relatively stable, the fluctuation range is small, and the gross profit margin of the product remains relatively stable. In 2024, the company's BMS main control chip CCFC2007PT, high-end domain control chip CCFC3007PT, airbag ignition drive chip CCL1600B, etc. have all been used for loading/installing, and several manufacturers are developing at designated locations based on the above chips. In the future, with the increase of fixed-point mass production projects, shipments are expected to continue to grow.